Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 488 of 5804
-
New cocktail targets tough leukemia mutations
Disease control Recruiting nowThis research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted…
Phase: PHASE1 • Sponsor: Richard Stone, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a new pill ease irritability in kids with autism?
Symptom relief Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Triple-Drug attack offers hope for Hard-to-Treat colorectal cancer
Disease control Recruiting nowA randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising combo aims to stall advanced breast cancer
Disease control Recruiting nowThis trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective …
Phase: PHASE3 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Nasal spray vaccine aims to block COVID-19 without needles
⭐️ VACCINE ⭐️ CompletedThe purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS…
Phase: PHASE2 • Sponsor: CyanVac LLC • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 12, 2026 00:00 UTC
-
One-shot radiation blast aims to zap liver tumors better
Disease control Recruiting nowThis international multi-centre phase 3 randomized control trial investigates whether giving a very high dose of radiation in a single treatment session (ultra-high dose: experimental) using advanced technology called MR-Linac is more effective than a high dose (control) for trea…
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Smart antibody monitoring could prevent pemphigus Flare-Ups
Disease control Recruiting nowPemphigus diseases are life-threatening chronic autoimmune blistering diseases characterized by split formation within the epidermis and surface-close epithelia accompanied by acantholysis. Autoantibodies (Abs) are mainly directed against two structural proteins of the epidermal/…
Phase: PHASE4 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug targets hidden cancer cells after colorectal cancer treatment
Disease control Recruiting nowTo investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
CAR-T cells take on rheumatoid arthritis in Head-to-Head trial
Disease control OngoingThe goal of this phase I/II clinical trial is to compare B-cell depletion by rituximab and anti-CD 19 CAR-T therapy in patients with rheumatoid arthritis. The main questions it aims to answer are: * To assess the safety of anti-CD19 CAR T cell therapy in subjects with active, AC…
Phase: PHASE1, PHASE2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug nipocalimab tested in 655 Sjogren's patients in major trial
Disease control OngoingThe purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New obesity drug ARO-INHBE enters human trials
Disease control Recruiting nowThis is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multipl…
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Lower dose of heated chemo may be just as effective for rare abdominal cancer
Disease control Recruiting nowThe Investigators are researching how to improve the treatment currently available for patients diagnosed with Pseudomyxoma Peritonei (PMP). This is a rare cancer that usually starts in the appendix and spreads around the abdomen. PMP is usually treated using a type of surgery c…
Phase: PHASE3 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Ovarian cancer: can a second round of niraparib after surgery keep tumors at bay?
Disease control Recruiting nowThe ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with oligometastatic progression (OMP) after first maintenance therap…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare MDS: targeted drug ivosidenib takes on standard therapy
Disease control Recruiting nowThis study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone …
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Scientists aim to find the perfect dose of resistance exercise for heart health
Prevention Recruiting nowA large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 m…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Vutrisiran shows promise for Long-Term control of rare heart condition
Disease control ENROLLING_BY_INVITATIONThe purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail aims to boost pancreatic cancer surgery success
Disease control Recruiting nowTo evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug could save transplanted kidneys from rejection
Disease control OngoingIn this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure. But even after a successful transplant, the body's immu…
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antiviral pill aims to keep High-Risk COVID patients out of hospital
Disease control Recruiting nowResearchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered cord blood cells take aim at stubborn colorectal cancer
Disease control Recruiting nowTo find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC